[S-8] Karyopharm Therapeutics Inc. Employee Benefit Plan Registration
Karyopharm Therapeutics Inc. filed a Form S-8 to register an additional 450,000 shares of common stock under its 2022 Equity Incentive Plan, as amended. The filing incorporates prior Form S-8 registrations for the same plan by reference and makes those shares available for issuance as awards to employees and directors. Exhibits listed include the Restated Certificate, Third Amended and Restated By-Laws, counsel opinion and consent, auditor consent, the amended plan text and a filing fee table; the registration statement is signed by the company’s authorized officers and directors.
Karyopharm Therapeutics Inc. ha depositato un modulo S-8 per registrare ulteriori 450.000 azioni ordinarie nell'ambito del suo Piano di Incentivi Azionari 2022, così come modificato. Il deposito incorpora per riferimento le precedenti registrazioni Form S-8 relative allo stesso piano e rende tali azioni disponibili per l'assegnazione come premi a dipendenti e amministratori. Gli allegati elencati includono il Certificato riformulato, il Terzo Statuto modificato e riformulato, il parere e il consenso del consulente legale, il consenso del revisore, il testo del piano emendato e una tabella delle commissioni di deposito; la dichiarazione di registrazione è firmata dagli amministratori e dagli ufficiali autorizzati della società.
Karyopharm Therapeutics Inc. presentó un formulario S-8 para registrar 450.000 acciones adicionales de acciones comunes bajo su Plan de Incentivos de Capital 2022, enmendado. La presentación incorpora por referencia registros Form S-8 previos del mismo plan y pone esas acciones a disposición para su adjudicación como incentivos a empleados y directores. Los anexos listados incluyen el Certificado reformulado, los Estatutos tercer enmendados y reformulados, la opinión y el consentimiento del asesor legal, el consentimiento del auditor, el texto del plan enmendado y una tabla de tasas de presentación; la declaración de registro está firmada por los directores y los funcionarios autorizados de la empresa.
Karyopharm Therapeutics Inc.는 수정된 2022 주식 인센티브 플랜 하에 추가로 450,000주의 보통주를 등록하기 위해 Form S-8을 제출했습니다. 이 제출서는 동일한 플랜에 대한 이전 Form S-8 등록들을 참조로 포함하고 있으며, 해당 주식들을 직원 및 이사에게 보상(상여)으로 발행할 수 있도록 제공합니다. 기재된 첨부문서에는 재작성된 증명서(Restated Certificate), 세 번째로 수정·재작성된 내규(Third Amended and Restated By-Laws), 법률자문 의견 및 동의서, 감사인 동의서, 수정된 플랜 문안 및 제출 수수료 표가 포함되어 있으며; 등록 명세서는 회사의 권한 있는 임원 및 이사들이 서명했습니다.
Karyopharm Therapeutics Inc. a déposé un formulaire S-8 pour enregistrer 450 000 actions ordinaires supplémentaires dans le cadre de son Plan d'Incitation en Actions 2022, tel qu'amendé. le dépôt incorpore par renvoi les enregistrements Form S-8 antérieurs relatifs au même plan et rend ces actions disponibles pour attribution en tant que récompenses aux employés et administrateurs. Les pièces jointes listées comprennent le certificat refondu, les statuts troisièmement modifiés et refondus, l'avis et le consentement du conseil juridique, le consentement de l'auditeur, le texte du plan amendé et un tableau des frais de dépôt ; la déclaration d'enregistrement est signée par les dirigeants et administrateurs autorisés de la société.
Karyopharm Therapeutics Inc. hat ein Formular S-8 eingereicht, um zusätzliche 450.000 Aktien der Stammaktien im Rahmen ihres 2022 Equity Incentive Plan, in geänderter Fassung zu registrieren. Die Einreichung bezieht sich durch Verweis auf frühere Form S-8-Registrierungen für denselben Plan und stellt diese Aktien zur Ausgabe als Zuweisungen an Mitarbeiter und Vorstandsmitglieder bereit. Aufgeführte Anhänge umfassen die neu gefasste Urkunde (Restated Certificate), die dritte geänderte und neu gefasste Satzung (Third Amended and Restated By-Laws), die Rechtsberatungsmeinung und deren Zustimmung, die Zustimmung des Wirtschaftsprüfers, den geänderten Plantext sowie eine Tabelle der Einreichungsgebühren; die Registrierungsunterlage ist von den bevollmächtigten leitenden Angestellten und Direktoren des Unternehmens unterzeichnet.
- Added 450,000 shares registered for issuance under the 2022 Equity Incentive Plan, expanding the plan's available award pool.
- Incorporates prior Form S-8 filings by reference, maintaining continuity of disclosure for the equity incentive program.
- Includes required legal and auditor consents and the amended plan text as exhibits, indicating formal compliance with filing requirements.
- Potential dilution to existing shareholders when the newly registered shares are issued under the plan.
- No financial or operational updates are provided in this filing; it does not address company performance or material transactions.
Insights
TL;DR: Registers 450,000 additional shares for employee/director awards; procedural filing with limited immediate financial impact.
The registration makes 450,000 common shares available for issuance under the 2022 Equity Incentive Plan, as amended, which is the formal step required before equity awards can be granted and settled. The filing incorporates prior S-8 filings by reference and includes the amended plan text as an exhibit, ensuring continuity of disclosure for equity compensation programs. Impact: neutral for current financial results; it increases the pool of shares that could dilute holders when awards are actually issued.
TL;DR: Administrative compliance filing with required legal and auditor consents; no governance changes disclosed.
The registration statement includes standard governance and legal exhibits: a Restated Certificate, By-Laws, legal opinion of counsel and related consent, auditor consent, power of attorney and the amended 2022 Equity Incentive Plan. Signatures from the company’s officers and directors are provided. There are no disclosures of leadership changes, material transactions, or financial metrics in this filing. Impact: not materially impactful to investors beyond increasing the reserve available for equity awards.
Karyopharm Therapeutics Inc. ha depositato un modulo S-8 per registrare ulteriori 450.000 azioni ordinarie nell'ambito del suo Piano di Incentivi Azionari 2022, così come modificato. Il deposito incorpora per riferimento le precedenti registrazioni Form S-8 relative allo stesso piano e rende tali azioni disponibili per l'assegnazione come premi a dipendenti e amministratori. Gli allegati elencati includono il Certificato riformulato, il Terzo Statuto modificato e riformulato, il parere e il consenso del consulente legale, il consenso del revisore, il testo del piano emendato e una tabella delle commissioni di deposito; la dichiarazione di registrazione è firmata dagli amministratori e dagli ufficiali autorizzati della società.
Karyopharm Therapeutics Inc. presentó un formulario S-8 para registrar 450.000 acciones adicionales de acciones comunes bajo su Plan de Incentivos de Capital 2022, enmendado. La presentación incorpora por referencia registros Form S-8 previos del mismo plan y pone esas acciones a disposición para su adjudicación como incentivos a empleados y directores. Los anexos listados incluyen el Certificado reformulado, los Estatutos tercer enmendados y reformulados, la opinión y el consentimiento del asesor legal, el consentimiento del auditor, el texto del plan enmendado y una tabla de tasas de presentación; la declaración de registro está firmada por los directores y los funcionarios autorizados de la empresa.
Karyopharm Therapeutics Inc.는 수정된 2022 주식 인센티브 플랜 하에 추가로 450,000주의 보통주를 등록하기 위해 Form S-8을 제출했습니다. 이 제출서는 동일한 플랜에 대한 이전 Form S-8 등록들을 참조로 포함하고 있으며, 해당 주식들을 직원 및 이사에게 보상(상여)으로 발행할 수 있도록 제공합니다. 기재된 첨부문서에는 재작성된 증명서(Restated Certificate), 세 번째로 수정·재작성된 내규(Third Amended and Restated By-Laws), 법률자문 의견 및 동의서, 감사인 동의서, 수정된 플랜 문안 및 제출 수수료 표가 포함되어 있으며; 등록 명세서는 회사의 권한 있는 임원 및 이사들이 서명했습니다.
Karyopharm Therapeutics Inc. a déposé un formulaire S-8 pour enregistrer 450 000 actions ordinaires supplémentaires dans le cadre de son Plan d'Incitation en Actions 2022, tel qu'amendé. le dépôt incorpore par renvoi les enregistrements Form S-8 antérieurs relatifs au même plan et rend ces actions disponibles pour attribution en tant que récompenses aux employés et administrateurs. Les pièces jointes listées comprennent le certificat refondu, les statuts troisièmement modifiés et refondus, l'avis et le consentement du conseil juridique, le consentement de l'auditeur, le texte du plan amendé et un tableau des frais de dépôt ; la déclaration d'enregistrement est signée par les dirigeants et administrateurs autorisés de la société.
Karyopharm Therapeutics Inc. hat ein Formular S-8 eingereicht, um zusätzliche 450.000 Aktien der Stammaktien im Rahmen ihres 2022 Equity Incentive Plan, in geänderter Fassung zu registrieren. Die Einreichung bezieht sich durch Verweis auf frühere Form S-8-Registrierungen für denselben Plan und stellt diese Aktien zur Ausgabe als Zuweisungen an Mitarbeiter und Vorstandsmitglieder bereit. Aufgeführte Anhänge umfassen die neu gefasste Urkunde (Restated Certificate), die dritte geänderte und neu gefasste Satzung (Third Amended and Restated By-Laws), die Rechtsberatungsmeinung und deren Zustimmung, die Zustimmung des Wirtschaftsprüfers, den geänderten Plantext sowie eine Tabelle der Einreichungsgebühren; die Registrierungsunterlage ist von den bevollmächtigten leitenden Angestellten und Direktoren des Unternehmens unterzeichnet.
FAQ
What did Karyopharm (KPTI) register on Form S-8?
How many shares were added to Karyopharm's equity incentive plan?
Does the filing include legal and auditor consents?
Will this filing change KPTI's reported earnings or operations?
Which equity plan governs the newly registered shares?
Who signed the registration statement for Karyopharm?
